The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 2 clinical trial on trametinib and low-dose dabrafenib in advanced pretreated BRAFV600/NRASQ61R/K/L wild-type melanoma (TraMel-WT): Interim efficacy and safety results.
 
Gil Awada
Employment - Abbott Laboratories (I)
Honoraria - Novartis
Consulting or Advisory Role - Novartis
Research Funding - Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; MSD Oncology; Novartis; Pfizer
 
Julia Katharina Schwarze
Honoraria - Novartis (Inst)
Travel, Accommodations, Expenses - Amgen; MSD Belgium
 
Jens Tijtgat
No Relationships to Disclose
 
Giuseppe Fasolino
No Relationships to Disclose
 
Hendrik Everaert
No Relationships to Disclose
 
Bart Neyns
Honoraria - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Roche
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pfizer/EMD Serono; Roche
Speakers' Bureau - Novartis
Research Funding - Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Roche